BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 38607055)

  • 1. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.
    Lee CH; Hsu KW; Hsieh YY; Li WT; Long Y; Lin CY; Chen SH
    Cells; 2024 Apr; 13(7):. PubMed ID: 38607055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
    Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
    Gonzalez MA; Olivas IM; Bencomo-Alvarez AE; Rubio AJ; Barreto-Vargas C; Lopez JL; Dang SK; Solecki JP; McCall E; Astudillo G; Velazquez VV; Schenkel K; Reffell K; Perkins M; Nguyen N; Apaflo JN; Alvidrez E; Young JE; Lara JJ; Yan D; Senina A; Ahmann J; Varley KE; Mason CC; Eide CA; Druker BJ; Nurunnabi M; Padilla O; Bajpeyi S; Eiring AM
    Clin Transl Med; 2022 Dec; 12(12):e1146. PubMed ID: 36536477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.
    Singh D; Vignat J; Lorenzoni V; Eslahi M; Ginsburg O; Lauby-Secretan B; Arbyn M; Basu P; Bray F; Vaccarella S
    Lancet Glob Health; 2023 Feb; 11(2):e197-e206. PubMed ID: 36528031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death detection methods: a systematic review and a categorical comparison.
    Kari S; Subramanian K; Altomonte IA; Murugesan A; Yli-Harja O; Kandhavelu M
    Apoptosis; 2022 Aug; 27(7-8):482-508. PubMed ID: 35713779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
    Mojtahedi H; Yazdanpanah N; Rezaei N
    Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
    Alves R; Gonçalves AC; Rutella S; Almeida AM; De Las Rivas J; Trougakos IP; Sarmento Ribeiro AB
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer
    Lin CL; Tsai ML; Chen YH; Liu WN; Lin CY; Hsu KW; Huang CY; Chang YJ; Wei PL; Chen SH; Huang LC; Lee CH
    Biomol Ther (Seoul); 2021 Sep; 29(5):551-561. PubMed ID: 34031270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX13 regulates cancer stem-like properties and tumorigenicity in hepatocellular carcinoma cells.
    Jiao H; Fang F; Fang T; You Y; Feng M; Wang X; Yin Z; Zhao W
    Am J Cancer Res; 2021; 11(3):760-772. PubMed ID: 33791152
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.